Price Alert

PTC Therapeutics Inc. (PTCT)

NASDAQ: PTCT · Real-Time Price · USD

48.59

-0.11 (-0.23%)

At close: Aug 15, 2025, 12:40 PM

PTC Therapeutics Statistics

Share Statistics

PTC Therapeutics has 79.26M shares outstanding. The number of shares has increased by 3.03% in one year.

Shares Outstanding	79.26M
Shares Change (YoY)	3.03%
Shares Change (QoQ)	0.49%
Owned by Institutions (%)	99.99%
Shares Floating	75.84M
Failed to Deliver (FTD) Shares	1,665
FTD / Avg. Volume	0.15%

Short Selling Information

The latest short interest is 5.77M, so 7.28% of the outstanding shares have been sold short.

Short Interest	5.77M
Short % of Shares Out	7.28%
Short % of Float	8.37%
Short Ratio (days to cover)	5.52

Valuation Ratios

The PE ratio is -9.55 and the forward PE ratio is -19.02. PTC Therapeutics's PEG ratio is 0.22.

PE Ratio	-9.55
Forward PE	-19.02
PS Ratio	4.3
Forward PS	3.9
PB Ratio	-3.16
P/FCF Ratio	-30.38
PEG Ratio	0.22

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for PTC Therapeutics.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.35, with a Debt / Equity ratio of -0.35.

Current Ratio	2.35
Quick Ratio	2.31
Debt / Equity	-0.35
Debt / EBITDA	-3.23
Debt / FCF	-3.41
Interest Coverage	-1.81

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$859.19K
Profits Per Employee	$-386.9K
Employee Count	939
Asset Turnover	0.47
Inventory Turnover	2.47

Taxes

Income Tax	176K
Effective Tax Rate	-0.05%

Stock Price Statistics

The stock price has increased by 38.29% in the last 52 weeks. The beta is 0.54, so PTC Therapeutics's price volatility has been higher than the market average.

Beta	0.54
52-Week Price Change	38.29%
50-Day Moving Average	49.41
200-Day Moving Average	47.57
Relative Strength Index (RSI)	38.53
Average Volume (20 Days)	1,126,419

Income Statement

In the last 12 months, PTC Therapeutics had revenue of 806.78M and earned -363.3M in profits. Earnings per share was -4.73.

Revenue	806.78M
Gross Profit	749.38M
Operating Income	-302.57M
Net Income	-363.3M
EBITDA	-120.46M
EBIT	-196.13M
Earnings Per Share (EPS)	-4.73

Full Income Statement

Balance Sheet

The company has 779.71M in cash and 389.3M in debt, giving a net cash position of 390.41M.

Cash & Cash Equivalents	779.71M
Total Debt	389.3M
Net Cash	390.41M
Retained Earnings	-3.65B
Total Assets	2.66B
Working Capital	1.72B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -107.69M and capital expenditures -6.5M, giving a free cash flow of -114.19M.

Operating Cash Flow	-107.69M
Capital Expenditures	-6.5M
Free Cash Flow	-114.19M
FCF Per Share	-1.49

Full Cash Flow Statement

Margins

Gross margin is 92.89%, with operating and profit margins of -37.5% and -45.03%.

Gross Margin	92.89%
Operating Margin	-37.5%
Pretax Margin	-45.01%
Profit Margin	-45.03%
EBITDA Margin	-14.93%
EBIT Margin	-37.5%
FCF Margin	-14.15%

Dividends & Yields

PTCT does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for PTCT is $66.5, which is 53.6% higher than the current price. The consensus rating is "Buy".

Price Target	$66.5
Price Target Difference	53.6%
Analyst Consensus	Buy
Analyst Count	13

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	1.74
Piotroski F-Score	7